Stock Price Forecast

Dec. 12, 2023


Forecasted Returns

7 Days Predict

30 Days Predict

90 Days Predict


Forecasted Market-Excess Returns

7 Days Predict

30 Days Predict

90 Days Predict

Loading Seagen Inc chart...

About the Company

seattle genetics, co-founded by clay siegall, is a biotechnology company leading the field of antibody-drug conjugates (adcs) for the treatment of cancer. our technology is designed to harness the targeting ability of monoclonal antibodies to deliver cell-killing agents directly to cancer cells. our lead program, adcetris® (brentuximab vedotin), is the first in a new class of adcs and, in collaboration with takeda pharmaceutical company limited, is approved in more than 55 countries. to expand on the adcetris opportunity, we are conducting a broad clinical development program to evaluate its therapeutic potential in a range of other lymphoma and non-lymphoma settings. seattle genetics is also advancing a robust pipeline of clinical-stage programs, including sgn-cd19a, sgn-cd33a, sgn-liv1a, sgn-cd70a, asg-22me, asg-15me and sea-cd40. seattle genetics has collaborations for its adc technology with a number of leading biotechnology and pharmaceutical companies, including abbvie, agensys

Exchange

NASDAQ

Website

seattlegenetics.com

$140M

Total Revenue

4K

Employees

$43B

Market Capitalization

-57.32

Price/Earning ratio

Fundamental Data and Insider Transactions (Quarterly data) Full Screen

Loading the fundamentals chart...

Latest $SGEN News

Pfizer-Acquired Seagen's Adcetris Combo Therapy Extends Overall Survival Versus Placebo In Patients With Most Common Type Of Lymphoma

on MSN ago, source:

Pfizer Inc (NYSE:PFE) announced that a Phase 3 study of the antibody-drug conjugate Adcetris (brentuximab vedotin) combined ...

Seagen Inc Ordinary Shares

4d ago, source: Morningstar

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

How investment banker Andrew Weisenfeld rode last year's healthcare M&A streak to the big leagues

5d ago, source:

Andrew Weisenfeld of MTS Health Partners breaks down the healthcare bank's growth plans after advising on Pfizer's $43 ...

Pfizer shutting down Seagen's $350M construction project in Everett

17d ago, source: The Business Journals

The site, located at 215 Shuksan Way, was part of the $43 billion acquisition of Bothell-based Seagen Inc. (Nasdaq: SGEN), which was completed in December. About 120 employees will be laid off as ...

Pfizer’s $43B Seagen Buy Starts to Pay Off with Adcetris Phase III Data in DLBCL

6d ago, source: BioSpace

Antibody-drug conjugate Adcetris, when used with rituximab or lenalidomide, improved overall survival in patients with ...

Pfizer bets on cancer drugs to recover from rapid decline of COVID business

on MSN ago, source:

Pfizer is pushing to be more involved in cancer drugs after a turbulent year marked by the rapid decline of its COVID ...

Pfizer: Seagen Acquisition Starting To Bear Fruit

6d ago, source:

Pfizer's oncology pipeline, including the Seagen acquisition and positive trial results, is expected to fuel long-term ...

Seagen Inc. (SGEN.MX)

29d ago, source: Yahoo Finance

The top three U.S. M&A deals of 2023 by deal value include, Exxon (XOM) acquiring Pioneer (PXD), Chevron's (CVX) acquisition of Hess (HES), and Pfizer (PFE) acquiring Seagen (SGEN), according to ...

Pfizer’s Seagen takeover faces EU investigation

6d ago, source: The Star

NEW YORK: Pfizer Inc’s proposed US$43bil (RM195bil) takeover of Seagen Inc will face an investigation from the European Union’s (EU) merger enforcer, as the bloc continues to scrutinise large ...

Biotech rally gets US$100bil M&A lift

4d ago, source:

A rash of dealmaking helped reverse the declining fortunes of biotech stocks over the last five months. And as AstraZeneca ...

These Drug Companies Are Going Nuclear to Fight Cancer

27d ago, source: Wall Street Journal

Pfizer’s $43 billion acquisition of biotech Seagen Inc. last year underscored how hot the field has become.

Latest Neutral (free) Forecasts

STRONG BUY BUY NEUTRAL SELL STRONG SELL ALL

Loading the latest forecasts...

My Portfolio

Loading your portfolio...